EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page

Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

by Sarah Moniz | Apr 10, 2018

Time for T? Immunoinformatics addresses the challenges of vaccine design for neglected tropical and emerging infectious diseases

Time for T? Immunoinformatics addresses the challenges of vaccine design for neglected tropical and emerging infectious diseases

by epivax3 | Oct 22, 2016

Expert Review of Vaccines. Resubmitted 3 Aug 2014. Full Text
An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8+ T cell epitopes

An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8+ T cell epitopes

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. 2015;11(9):2322-8 .PMID: 26107442
Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma

Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma

by epivax3 | Oct 22, 2016

Vaccine. 2015;33(10):1256-66 PMCID: PMC4331251
Preclinical development of HIvax: human survivin Highly Immunogenic vaccines

Preclinical development of HIvax: human survivin Highly Immunogenic vaccines

by epivax3 | Oct 22, 2016

« Older Entries

Recent Posts

  • From Kyoto, with Love
  • EpiVax Turns 25!
  • Happy Valentine’s Day! And don’t argue with Chatbots!
  • ISPRI in silico Toolkit in the Literature
  • Platform shoes, Bellbottoms and #CrueltyFreeFDA!

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562